Alkermes Plc (ALKS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alkermes Plc (ALKS) has a cash flow conversion efficiency ratio of 0.080x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($145.18 Million) by net assets ($1.81 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Alkermes Plc for the company's overall valuation and market capitalisation.
Alkermes Plc - Cash Flow Conversion Efficiency Trend (1991–2025)
This chart illustrates how Alkermes Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alkermes Plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alkermes Plc ranked by their cash flow conversion efficiency. Explore Alkermes Plc cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
INPOST S.A. EO -01
F:669
|
0.070x |
|
Steel Authority of India Limited
NSE:SAIL
|
0.132x |
|
Zurn Elkay Water Solutions Corporation
NYSE:ZWS
|
0.064x |
|
IOI Corporation Bhd
KLSE:1961
|
0.028x |
|
WT Microelectronics Co Ltd
TW:3036
|
-0.075x |
|
Beacon Roofing Supply Inc
NASDAQ:BECN
|
-0.070x |
|
Vicinity Centres
AU:VCX
|
0.028x |
|
ICICI Lombard General Insurance Company Limited
NSE:ICICIGI
|
0.027x |
Annual Cash Flow Conversion Efficiency for Alkermes Plc (1991–2025)
The table below shows the annual cash flow conversion efficiency of Alkermes Plc from 1991 to 2025. View ALKS stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.82 Billion | $520.75 Million | 0.286x | -4.51% |
| 2024-12-31 | $1.46 Billion | $439.12 Million | 0.300x | -10.18% |
| 2023-12-31 | $1.20 Billion | $401.35 Million | 0.334x | +1555.17% |
| 2022-12-31 | $1.04 Billion | $21.04 Million | 0.020x | -77.95% |
| 2021-12-31 | $1.11 Billion | $101.72 Million | 0.091x | +17.75% |
| 2020-12-31 | $1.07 Billion | $82.84 Million | 0.078x | +16.92% |
| 2019-12-31 | $1.09 Billion | $72.08 Million | 0.066x | -21.66% |
| 2018-12-31 | $1.17 Billion | $99.28 Million | 0.085x | +431.28% |
| 2017-12-31 | $1.20 Billion | $19.19 Million | 0.016x | +130.24% |
| 2016-12-31 | $1.21 Billion | $-63.80 Million | -0.053x | -71.78% |
| 2015-12-31 | $1.31 Billion | $-40.36 Million | -0.031x | -485.09% |
| 2014-12-31 | $1.40 Billion | $11.14 Million | 0.008x | -90.79% |
| 2013-12-31 | $1.07 Billion | $92.20 Million | 0.087x | -34.86% |
| 2012-12-31 | $952.37 Million | $126.55 Million | 0.133x | +4671.29% |
| 2011-12-31 | $853.85 Million | $-2.48 Million | -0.003x | +80.71% |
| 2010-12-31 | $392.02 Million | $-5.91 Million | -0.015x | +49.24% |
| 2009-12-31 | $412.62 Million | $-12.25 Million | -0.030x | -135.97% |
| 2008-12-31 | $419.23 Million | $34.59 Million | 0.083x | -40.62% |
| 2007-12-31 | $305.31 Million | $42.42 Million | 0.139x | -36.16% |
| 2006-12-31 | $384.65 Million | $83.73 Million | 0.218x | -64.09% |
| 2005-12-31 | $192.24 Million | $116.53 Million | 0.606x | +103.36% |
| 2004-12-31 | $4.11 Million | $-74.25 Million | -18.058x | -246.28% |
| 2003-12-31 | $18.84 Million | $-98.25 Million | -5.215x | -957.19% |
| 2002-12-31 | $98.82 Million | $-48.75 Million | -0.493x | +32.56% |
| 2001-12-31 | $58.35 Million | $-42.68 Million | -0.731x | -392.56% |
| 2000-12-31 | $121.14 Million | $-17.99 Million | -0.148x | +27.45% |
| 1999-12-31 | $161.37 Million | $-33.03 Million | -0.205x | -133.92% |
| 1998-12-31 | $162.85 Million | $-14.25 Million | -0.088x | -1183.18% |
| 1997-12-31 | $166.69 Million | $-1.14 Million | -0.007x | +96.86% |
| 1996-12-31 | $79.15 Million | $-17.18 Million | -0.217x | -32.13% |
| 1995-12-31 | $33.49 Million | $-5.50 Million | -0.164x | +61.74% |
| 1994-12-31 | $21.20 Million | $-9.10 Million | -0.429x | -11.32% |
| 1993-12-31 | $31.90 Million | $-12.30 Million | -0.386x | -206.54% |
| 1992-12-31 | $47.70 Million | $-6.00 Million | -0.126x | +84.92% |
| 1991-12-31 | $54.20 Million | $-45.20 Million | -0.834x | -- |
About Alkermes Plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and … Read more